Literature DB >> 19221309

The Parkinson chimera.

Andrew J Lees1.   

Abstract

Although our concepts of what causes Parkinson disease (PD) are ever changing and the hunt for a reliable biomarker continues, the clinical picture remains as distinctive as when the malady was first described by James Parkinson and the neurologic Grand Masters of the nineteenth century. Hyposmia and visual hallucinations, however, can now be added as additional features of the clinical syndrome which may be helpful in distinguishing PD from atypical parkinsonism, as well as the growing list of causes of secondary parkinsonism. Selective vulnerability of catecholaminergic long axon projection neurons (part of the isodendritic core) in PD is an important, if recently somewhat neglected, fact and correlation of the severity of nigral loss with bradykinesia and rigidity is the only very reliable anatomo-clinical correlation. Although the Lewy body seems to be closely linked with our notion of PD as a clinicopathologic nosological entity, its role in the pathogenesis of the disorder is still obscure and hotly debated. Its presence in some of the long-surviving grafted neurons in fetal implants may provide important insights into its role in the disease process. Although Braak's hypothesis implicating the medulla oblongata as an obligate trigger for the subsequent spread of the pathologic process has generated much interest and encouraged more research, it seems unlikely as an explanation for the natural history of PD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19221309     DOI: 10.1212/WNL.0b013e318198daec

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

Review 1.  Interplay Between Exosomes, microRNAs and Toll-Like Receptors in Brain Disorders.

Authors:  Vera Paschon; Silvia Honda Takada; Juliane Midori Ikebara; Erica Sousa; Reza Raeisossadati; Henning Ulrich; Alexandre Hiroaki Kihara
Journal:  Mol Neurobiol       Date:  2015-04-11       Impact factor: 5.590

Review 2.  The significance of neuronal lateralisation in Parkinson's disease.

Authors:  P Riederer; J Sian-Hülsmann
Journal:  J Neural Transm (Vienna)       Date:  2012-02-26       Impact factor: 3.575

3.  Neurochemical phenotypes of myenteric neurons in the rhesus monkey.

Authors:  Ali Reza Noorian; Georgia M Taylor; Dana M Annerino; James G Greene
Journal:  J Comp Neurol       Date:  2011-12-01       Impact factor: 3.215

4.  Clinical progression in Parkinson disease and the neurobiology of axons.

Authors:  Hsiao-Chun Cheng; Christina M Ulane; Robert E Burke
Journal:  Ann Neurol       Date:  2010-06       Impact factor: 10.422

5.  New MRI Biomarkers Advance the Characterization of Parkinson Disease.

Authors:  David A Ziegler; Suzanne Corkin
Journal:  Eur Neurol Rev       Date:  2013

6.  Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport.

Authors:  Eric C Freundt; Nate Maynard; Eileen K Clancy; Shyamali Roy; Luc Bousset; Yannick Sourigues; Markus Covert; Ronald Melki; Karla Kirkegaard; Michel Brahic
Journal:  Ann Neurol       Date:  2012-10       Impact factor: 10.422

7.  Essential tremor is not a neurodegenerative disease.

Authors:  Ali H Rajput; Charles H Adler; Holly A Shill; Alex Rajput
Journal:  Neurodegener Dis Manag       Date:  2012-06

8.  Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease.

Authors:  David A Ziegler; Julien S Wonderlick; Paymon Ashourian; Leslie A Hansen; Jeremy C Young; Alex J Murphy; Cecily K Koppuzha; John H Growdon; Suzanne Corkin
Journal:  JAMA Neurol       Date:  2013-02       Impact factor: 18.302

9.  Transglutaminase activation in neurodegenerative diseases.

Authors:  Thomas M Jeitner; Nancy A Muma; Kevin P Battaile; Arthur Jl Cooper
Journal:  Future Neurol       Date:  2009-07-01

Review 10.  Molecular and clinical prodrome of Parkinson disease: implications for treatment.

Authors:  Anthony H V Schapira; Eduardo Tolosa
Journal:  Nat Rev Neurol       Date:  2010-05-18       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.